High-throughput cell-based screening for hepatitis C virus NS3/4A protease inhibitors

被引:13
|
作者
Lee, JC
Yu, MC
Lien, TW
Chang, CF
Hsu, JTA
机构
[1] Natl Hlth Res Inst, Div Biotechnol & Pharmaceut Res, Zhunan Town 350, Miaoli County, Taiwan
[2] Natl Tsing Hua Univ, Dept Chem Engn, Hsinchu, Taiwan
关键词
D O I
10.1089/adt.2005.3.385
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Hepatitis C virus ( HCV) encodes a viral protease, nonstructural (NS) 3/4A, that is critical for virus maturation. Although NS3/4A has emerged as a promising target for anti-HCV drug discovery, no anti-HCV therapy has succeeded yet based on inhibition of NS3/4A. We have previously shown that EG(Delta 4AB) SEAP, a reporter consisting of enhanced green fluorescent protein ( EG), the NS3-NS4A protease decapeptide recognition sequence (Delta 4AB), and secreted alkaline phosphatase ( SEAP), is an efficient reporter for reflecting NS3/4A proteolytic activity inside cells. In this study, we describe the generation and characterization of a stable cell line, 293E-EG( Delta 4AB) SEAP-NS3/4A, which constitutively expresses EG(Delta 4AB) SEAP reporter protein and NS3/4A protease. The reporter assay is validated with the compound BILN 2061, a specific and potent peptidomimetic inhibitor of the HCV NS3 protease. Additionally, we show here that this cell line allows screening for NS3/4A protease activity of living cells in 96-well plate format, with a Z factor >0.6. Thus, this cell-based assay may be used for high-throughput screening of chemical libraries.
引用
收藏
页码:385 / 392
页数:8
相关论文
共 50 条
  • [1] Hepatitis C virus NS3/4a protease inhibitors
    McCauley, John A.
    Rudd, Michael T.
    CURRENT OPINION IN PHARMACOLOGY, 2016, 30 : 84 - 92
  • [2] Development of cell-based assays for in vitro characterization of hepatitis C virus NS3/4A protease inhibitors
    Chung, V
    Carroll, AR
    Gray, NM
    Parry, NR
    Thommes, PA
    Viner, KC
    D'Souza, EA
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (04) : 1381 - 1390
  • [3] Cell-based assay for inhibitors of Hepatitis C Virus NS3 protease
    Chung, V
    D'Souza, E
    Carroll, AR
    ANTIVIRAL RESEARCH, 2002, 53 (03) : A73 - A73
  • [4] Hepatitis C virus NS3/4A protease
    Kwong, AD
    Kim, JL
    Rao, G
    Lipovsek, D
    Raybuck, SA
    ANTIVIRAL RESEARCH, 1998, 40 (1-2) : 1 - 18
  • [5] Hepatitis C virus NS3/4A protease
    Kwong, AD
    CURRENT OPINION IN INFECTIOUS DISEASES, 1997, 10 (06) : 485 - 490
  • [6] In Silico Screening for Potent Inhibitors against the NS3/4A Protease of Hepatitis C Virus
    Meeprasert, Arthitaya
    Rungrotmongkol, Thanyada
    Li, Mai Suan
    Hannongbua, Supot
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (21) : 3465 - 3477
  • [7] DEVELOPMENT OF A CELL-BASED ASSAY FOR MONITORING HEPATITIS C VIRUS NS3/4A PROTEASE ACTIVITY
    Lei, Y. F.
    Yin, W.
    Yang, J.
    Lv, X.
    Wei, S. H.
    An, Q. X.
    Hu, X. B.
    Xu, Z. K.
    ACTA VIROLOGICA, 2008, 52 (03) : 133 - 141
  • [8] A high-throughput radiometric assay for hepatitis C virus NS3 protease
    Cerretani, N
    Di Renzo, L
    Serafini, S
    Vitelli, A
    Gennari, N
    Bianchi, E
    Pessi, A
    Urbani, A
    Colloca, S
    De Francesco, R
    Steinkühler, C
    Altamura, S
    ANALYTICAL BIOCHEMISTRY, 1999, 266 (02) : 192 - 197
  • [9] Bismacrocyclic Inhibitors of Hepatitis C NS3/4a Protease
    McCauley, John A.
    Rudd, Michael T.
    Nguyen, Kevin T.
    McIntyre, Charles J.
    Romano, Joseph J.
    Bush, Kimberly J.
    Varga, Sandor L.
    Ross, Charles W., III
    Carroll, Steven S.
    DiMuzio, Jillian
    Stahlhut, Mark W.
    Olsen, David B.
    Lyle, Terry A.
    Vacca, Joseph P.
    Liverton, Nigel J.
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2008, 47 (47) : 9104 - 9107
  • [10] Virtual Screening of Telaprevir and Danoprevir Derivatives for Hepatitis C Virus NS3/4A Protease Inhibitors
    Sarkar, Kaushik
    Das, Rajesh Kumar
    LETTERS IN DRUG DESIGN & DISCOVERY, 2024, 21 (04) : 809 - 822